The question most people type is “does alpha-lipoic acid lower blood sugar,” but the better question is what kind of blood sugar change the studies measured, in whom, and for how long.
Quick answer: Alpha-lipoic acid (ALA) has been tested in dozens of small trials in people with type 2 diabetes or insulin resistance. Pooled results suggest modest average improvements in fasting glucose and insulin sensitivity markers, while effects on A1C are smaller and inconsistent. The evidence is stronger for nerve symptoms than for glucose control, and averages from short trials are not a prediction of what will happen in your body.
Why people with prediabetes and type 2 look at ALA
ALA is a sulfur-containing compound your body makes in small amounts. It sits inside mitochondria as a helper for enzymes that turn glucose into energy. In the lab it behaves as an antioxidant, and it can increase glucose uptake into muscle cells through some of the same signaling steps insulin uses.
That mechanism story is what sells bottles. It also happens to be the same kind of story that sells a lot of supplements that never pan out in humans. So the useful move is to set the mechanism aside and look at what happened when people took it. If you are still getting oriented on what insulin resistance is, the insulin resistance guide covers the basics, and the supplements for metabolic syndrome hub puts ALA next to the other options people ask about.
What the research actually shows
There are three layers of evidence, and they do not all say the same thing.
Mechanistic and animal studies. Plentiful and positive. They show ALA improving glucose uptake and insulin signaling in cells and rodents. They tell you almost nothing about what a capsule does in an adult with a fasting glucose of 112.
Randomized controlled trials in humans. Most are small, often 20 to 100 participants, and short, often 4 to 12 weeks, with a handful running six months or longer. Doses were usually 300 to 1,200 mg per day by mouth, and some older trials gave 600 mg intravenously, which is not the same as swallowing a capsule. Some trials reported lower fasting glucose and lower HOMA-IR scores (a calculated insulin resistance index you can explore with the HOMA-IR calculator). Others found no difference from placebo.
Meta-analyses. Several pooled analyses of these trials have been published. The pattern across them is a small average reduction in fasting glucose, a small average reduction in fasting insulin and HOMA-IR, and a small or non-significant change in A1C. When an A1C effect does show up, it tends to be a fraction of a percentage point on average. Averages are not personal results: some participants in those trials changed more, some not at all, and the pooled number is a blend.
What the research does not show is just as important. There is no large, long-term trial showing that ALA changes progression from prediabetes to diabetes, reduces complications, or substitutes for any part of standard care. Trial quality is mixed, several studies came from a small number of research groups, and publication bias (positive results get published, null results sit in a drawer) is a known problem in this literature. You can scan the primary studies yourself through a PubMed search for alpha-lipoic acid and type 2 diabetes.
Why the A1C number moves less than the fasting number
This confuses a lot of people. If fasting glucose drops, shouldn’t A1C follow?
Not necessarily. A1C reflects average glucose over roughly three months, including after-meal spikes, and most ALA trials were too short for A1C to fully reflect any change. ALA is also cleared from the blood quickly, in about an hour, so a once-a-day dose may influence glucose for part of the day and not the rest. A fasting measurement taken the next morning captures a different window than an A1C does. The A1C and glucose guide explains what each number can and cannot tell you.
The practical point: if you see a product page quoting a fasting glucose result from one trial as if it were an A1C promise, that is a marketing choice, not a research finding.
How to read an ALA label
A few things matter more than the front-of-bottle claims.
Form. Most products are racemic ALA, a 50/50 mix of two mirror-image molecules called R and S. Some sell R-ALA alone at a higher price. Nearly all of the blood sugar trials used the racemic form, which is covered in detail in R-ALA vs. regular alpha-lipoic acid.
Amount per serving, and servings per day. A label that says 600 mg may mean two capsules of 300 mg. Compare the per-day total to what trials used, not the per-capsule number.
Third-party testing. Look for a seal from an independent testing program rather than a self-declared “lab tested” line. Metabolic Clarity Labs sells berberine, not ALA, and you should hold any MCL product to exactly this same standard.
What is not on the label. The label will not tell you that ALA absorbs better on an empty stomach, or that absorption from oral capsules is only about 30 percent to begin with. The dosage and timing article goes through what the trials did about that.
Doses as studied, not as advice
Trials looking at glucose and insulin sensitivity commonly used 300 to 600 mg per day, with some using 1,200 mg or more divided across the day. The neuropathy trials, which are a separate body of evidence described in ALA and diabetic neuropathy, settled around 600 mg per day as the dose with the best balance of effect and tolerability. None of this is a recommendation for you. The right amount, and whether any amount makes sense alongside what you are already taking, is a question for your prescriber or pharmacist.
Safety and interactions
ALA is generally well tolerated in trials at the doses above, with nausea, stomach upset, and occasional skin rash being the most common complaints. A rare but serious reaction called insulin autoimmune syndrome has been reported, in which the immune system makes antibodies against insulin and causes unpredictable low blood sugar; it has been documented mostly in people of Japanese and Korean ancestry with a specific genetic marker. The full list of concerns, including thyroid medication and chemotherapy, is in ALA side effects and interactions.
Hypoglycemia warning: Combining any blood-sugar-active supplement with insulin, sulfonylureas, or other glucose-lowering medicines can push glucose too low. Symptoms include shakiness, sweating, confusion, and a fast heartbeat. Do not add a supplement to a medication plan without your prescriber’s knowledge.
Specific interactions worth naming: ALA may lower blood glucose additively with insulin, sulfonylureas, and other diabetes drugs; it may affect thyroid hormone levels and is usually separated from levothyroxine by several hours; and because it is an antioxidant, oncologists generally ask patients to avoid it during chemotherapy or radiation unless they have cleared it. For a broad medication overview, the MedlinePlus entry on alpha-lipoic acid is a reasonable starting place.
Questions to bring to your appointment
- Given my current fasting glucose, A1C, and medications, is there any reason ALA would be unsafe for me specifically?
- I take (name your diabetes medicine). If I added ALA, how would we watch for low blood sugar, and what reading should make me stop?
- I take thyroid medication. How far apart would I need to take them, and would you want to recheck my TSH?
- If I tried it for 12 weeks, which lab values would tell us whether it did anything, and when would we recheck them?
- Is there a reason to prioritize this over the changes to food, movement, or sleep we already discussed?
- Are there any upcoming treatments, surgeries, or chemotherapy where I should stop it beforehand?
ALA is one of the more-studied supplements in metabolic health, and also one where the gap between the mechanism story and the human trial results is easy to miss. Reading the prediabetes guide alongside this article will give you a better sense of where a supplement question fits in the larger picture.
About the author: Charles Kirkland is the founder of Metabolic Clarity Labs and author of The Journey Back. He is not a physician. This is general education, not a medically reviewed treatment plan.
Sources checked October 29, 2026. Discuss personal decisions with a qualified clinician or pharmacist. Do not start, stop, or change prescribed treatment based on this article.
Related reading: Supplements for Insulin Resistance.
Leave a Reply